ライフサイエンスコーパス: thyrotropin

1 ituitary hormones follitropin, lutropin, and thyrotropin.

2 have mild compensated thyroid resistance to thyrotropin action, not subclinical autoimmune primary h

3 These deficiencies include growth hormone, thyrotropin, adrenocorticotropin and gonadotropin defici

4 lts were found for low-dose radioiodine plus thyrotropin alfa (84.3%) versus high-dose radioiodine pl

5 drawal (87.6%) or high-dose radioiodine plus thyrotropin alfa (90.2%).

6 the high-dose group (P=0.007) and 23% in the thyrotropin alfa group versus 30% in the group undergoin

7 oup receiving the high dose and 87.1% in the thyrotropin alfa group versus 86.7% in the group undergo

8 radioiodine, each in combination with either thyrotropin alfa or thyroid hormone withdrawal before ab

9 Low-dose radioiodine plus thyrotropin alfa was as effective as high-dose radioiodi

10 using either recombinant human thyrotropin (thyrotropin alfa) or thyroid hormone withdrawal.

11 After stimulation with thyrotropin alfa, dosimetry with iodine-124 positron-emi

12 ss provided blood samples for measurement of thyrotropin and free thyroxine (T(4)).

13 Thyrotropin and free thyroxine should be measured and, w

14 nfirmed or excluded by measurements of serum thyrotropin and free thyroxine.

15 The use of recombinant human thyrotropin and low-dose (1.1 GBq) postoperative radioio

16 lites were largely inversely associated with thyrotropin and positively associated with free and tota

17 erum concentrations of the pituitary hormone thyrotropin and the thyroid hormones thyroxine and triio

18 l hypothyroidism (characterized by low serum thyrotropin and thyroxine concentrations) in a patient w

19 e divergence of lutropins, follitropins, and thyrotropins and the speciation of teleost fish may have

20 mone withdrawal and use of recombinant human thyrotropin) and two radioiodine ((131)I) doses (i.e., a

21 s a result of abnormal central regulation of thyrotropin, and also develop profound hearing loss.

22 d subacute thyroiditis, tumours that secrete thyrotropin, and drug-induced thyroid dysfunction, are a

23 ent on the pituitary hormones lutropin (LH), thyrotropin, and pro-opiomelanocortin.

24 h occasion, serum thyroxine, free thyroxine, thyrotropin, and thyroxine-binding globulin were measure

25 le for thyroid-stimulating hormone (TSH; ie, thyrotropin) as an inductive signal for tumor necrosis f

26 The introduction of sensitive thyrotropin assays and free thyroid hormone measurements

27 The action of thyrotropin at the thyroid cell was assessed as a growth

28 glycoprotein hormone subunit (alpha-GSU) and thyrotropin beta subunit (TSH-beta) genes is stimulated

29 vitro, LGD346 suppressed the activity of the thyrotropin beta-subunit gene promoter in thyrotrophs by

30 lective ligand LGD346 on the activity of the thyrotropin beta-subunit gene promoter.

31 of the growth hormone, prolactin (PRL), and thyrotropin-beta genes.

32 A-subunit adenovirus developed TSHR Abs with thyrotropin-binding inhibitory activity, although at low

33 nutes during the night of sleep deprivation, thyrotropin bioactivity, the thyrotropin response to pro

34 ypothesized and confirmed that TSAb (but not thyrotropin-blocking autoantibodies [TBAb's]) also poorl

35 /=18 years) who had at least two creatinine, thyrotropin, calcium, glycated haemoglobin, or lithium m

36 levothyroxine was increased to maintain the thyrotropin concentration at preconception values throug

37 The mean serum thyrotropin concentration declined from 2.2 mU per liter

38 /-4 pmol per liter, P<0.001) and their serum thyrotropin concentration increased from 0.9+/-1.1 to 3.

39 the fully rested condition (p<0.02), as were thyrotropin concentrations (p<0.01).

40 We then located 47 women with serum thyrotropin concentrations at or above the 99.7th percen

41 yroid function, the serum free thyroxine and thyrotropin concentrations did not change, whereas at 12

42 The serum thyrotropin concentrations increased to more than 7 micr

43 as people without thyroid disease age; serum thyrotropin concentrations may surpass the upper limit o

44 were no significant differences in neonatal thyrotropin concentrations of heel samples between mothe

45 Mean (95% CI) thyrotropin concentrations of neonates born to mothers w

46 The children of the 62 women with high serum thyrotropin concentrations performed slightly less well

47 Nocturnal serum thyrotropin concentrations were consistently higher in r

48 median maternal urinary iodine and neonatal thyrotropin concentrations, along with other relevant da

49 ary hormones lutropin (LH), follitropin, and thyrotropin constitute the family of glycoprotein hormon

50 Thyrotropin-dependent cell growth and DNA synthesis were

51 00E) did not induce growth in the absence of thyrotropin despite increasing DNA synthesis, which is l

52 Advances related to thyrotropin during 1999 included better understanding of

53 We measured serum thyrotropin every 15 minutes during the night of sleep d

54 We propose that if assays for thyrotropin, free T3, and free T4 are all done, knowledg

55 Maternal thyroid hormone levels (thyrotropin, free thyroxine, thyroid peroxidase antibodi

56 ones, like thyroid-stimulating hormone (TSH; thyrotropin), have only recently been reported, and none

57 iogonadotropin, human follitropin, and human thyrotropin heterodimers occurs in this fashion, indicat

58 To gain insight into the thyrotropin hormone (TSH) receptor (TSHR) cleavage, we s

59 eered the first superactive analogs of human thyrotropin (hTSH) by using a novel design strategy.

60 serum thyroid hormones and suppressed serum thyrotropin in almost all cases.

61 ly postpartum period; however, the values of thyrotropin in cord samples of neonates born to mothers

62 Initial clinical use of recombinant thyrotropin in evaluation of thyroid cancer recurrence w

63 A single measurement of low serum thyrotropin in individuals aged 60 years or older is ass

64 The bioactivity of thyrotropin in nonresponders was significantly greater t

65 , compared with heel blood samples, neonatal thyrotropin in samples collected from the cord are more

66 We measured concentration of thyrotropin in serum at baseline in 1988-89.

67 In 1996 and 1997, we measured thyrotropin in stored serum samples collected from 25,21

68 ma T3 and an "inappropriately normal" plasma thyrotropin in the absence of intrinsic disease of the h

69 Low serum thyrotropin, in combination with normal concentrations o

70 on; its level in the thyroid is regulated by thyrotropin-increased cyclic AMP levels.

71 aminotriazole, in which increased release of thyrotropin induces massive colloid endocytosis.

72 nd for hypothyroxinemia, defined as a normal thyrotropin level (0.08 to 3.99 mU per liter) and a low

73 t was adjusted as needed to achieve a target thyrotropin level of 0.1 to 1.0 mIU per liter.

74 for subclinical hypothyroidism, defined as a thyrotropin level of 4.00 mU or more per liter and a nor

75 The median serum thyrotropin level was 5.7 mU/L (interquartile range, 4.8

76 The mean (+/-SD) thyrotropin level was 6.40+/-2.01 mIU per liter at basel

77 o had persisting subclinical hypothyroidism (thyrotropin level, 4.60 to 19.99 mIU per liter; free thy

78 ease), with dose adjustment according to the thyrotropin level; 369 patients were assigned to receive

79 roid-stimulating hormone (TSH; also known as thyrotropin) level and these outcome parameters.

80 Thyrotropin levels above the 97.5th percentile, free T(4

81 ommencing at 25 ug titrated to aim for serum thyrotropin levels between 0.4 and 2.5 mU/L or identical

82 ts with subclinical hypothyroidism and serum thyrotropin levels of 10 mU/L or higher or for young and

83 Serum thyrotropin levels remained similar and within the norma

84 However, serum thyrotropin levels rise as people without thyroid diseas

85 Thereafter, serum thyrotropin levels should be monitored and the levothyro

86 s, and that switching back to tablets caused thyrotropin levels to worsen, leads us to believe that a

87 of free thyroxine coexisting with reference thyrotropin levels, and children's symptoms of ADHD.

88 raphic factors, systemic medical conditions, thyrotropin levels, and medical and surgical interventio

89 ality within the cohort according to initial thyrotropin measurement.

90 hyrotropin-releasing hormone in synthesis of thyrotropin molecules with mature glycosylation, and the

91 er first measurement in those with low serum thyrotropin (n471).

92 hypothyroidism, defined as an elevated serum thyrotropin (often referred to as thyroid-stimulating ho

93 yroxine dose was adjusted to attain a normal thyrotropin or free T4 level (depending on the trial), w

94 No change in levels of serum thyrotropin or triiodothyronine was detected, although t

95 pled receptors with dissociable agonists for thyrotropin, parathyroid hormone, and sphingosine-1-phos

96 eptor staining was visible in prolactin- and thyrotropin-producing cells in rat pituitary tissue from

97 that such ligands could reversibly suppress thyrotropin production by a thyroid hormone-independent

98 xpressing either mouse (mM12 cells) or human thyrotropin receptor (TSHR) (hM12 cells).

99 Thyrotropin receptor (TSHR) Ab's of the stimulating vari

100 The large TSH-bound ectodomain of the thyrotropin receptor (TSHR) activates the transmembrane

101 es' disease (GD), autoantibodies bind to the thyrotropin receptor (TSHR) and cause hyperthyroidism.

102 vity of AAbeta1AR and AAM2R with stimulating thyrotropin receptor (TSHR) antibodies was evaluated bef

103 We studied cell surface thyrotropin receptor (TSHR) by biotinylating proteins on

104 the glycoprotein hormone receptors, only the thyrotropin receptor (TSHR) cleaves (at two sites) into

105 between the cysteine-rich N terminus of the thyrotropin receptor (TSHR) ectodomain and epidermal gro

106 s, the detection of circulating DTC cells by thyrotropin receptor (TSHR) mRNA measurement distinguish

107 g mutations are, however, more common in the thyrotropin receptor (TSHR) than in its downstream trans

108 Abs that stimulate the thyrotropin receptor (TSHR), the cause of Graves' hypert

109 The thyrotropin receptor (TSHR), the major autoantigen in Gr

110 y caused by autoantibodies that activate the thyrotropin receptor (TSHR).

111 ng autoantibodies (TSAb's) that activate the thyrotropin receptor (TSHR).

112 yroid-stimulating Abs (TSAbs) activating the thyrotropin receptor (TSHR).

113 Activating anti-thyrotropin receptor Abs are responsible for hyperthyroi

114 of patients developed antibodies against the thyrotropin receptor and carbimazole-responsive autoimmu

115 activation of shared autoantigens including thyrotropin receptor and insulin-like growth factor-1 re

116 Thyrotropin receptor antibodies (TRAb) concentration was

117 Thyrotropin receptor antigen on fibroblasts diffusely in

118 responsiveness associated with inhibition of thyrotropin receptor gene expression.

119 odide symporter, thyroid peroxidase, TG, and thyrotropin receptor genes.

120 elix scaffold, which endowed the substituted thyrotropin receptor intracellular domain elements with

121 ies of glycoprotein hormone receptors (e.g., thyrotropin receptor) and biogenic amine receptors (e.g.

122 The thyrotropin receptor, also known as the thyroid-stimulat

123 ss a point mutation in the gene encoding the thyrotropin receptor, and affected animals are congenita

124 ot impair key activation steps distal to the thyrotropin receptor, such as forskolin-induced adenylyl

125 ) B cells produce pathogenic Abs against the thyrotropin receptor.

126 nction and gain-of-function mutations of the thyrotropin receptor.

127 he intracellular domain of a model GPCR, the thyrotropin receptor.

128 sembled models of lutropin, follitropin, and thyrotropin receptors by aligning models of their LRD, T

129 xplains how substitutions in follitropin and thyrotropin receptors distant from their apparent ligand

130 led receptors homologous to gonadotropin and thyrotropin receptors have recently been identified and

131 distinguish lutropin (LHR), follitropin, and thyrotropin receptors.

132 The rat prepro-thyrotropin releasing hormone (TRH) 178-199 is derived f

133 y cooperative interaction between leptin and thyrotropin releasing hormone (TRH) in the hindbrain to

134 istry and RT-PCR demonstrated a reduction of Thyrotropin Releasing Hormone (TRH) in the hypothalamus

135 The biogenesis of rat thyrotropin releasing hormone (TRH) involves the process

136 gene expression of Sim1, oxytocin (OXT) and thyrotropin releasing hormone (TRH) was reduced by about

137 Thyrotropin releasing hormone (TRH), a water soluble dru

138 ith the calcium ionophore ionomycin, or with thyrotropin releasing hormone or vasoactive intestinal p

139 r neurotransmitters such as glutamate, GABA, thyrotropin releasing hormone, and substance P encoded b

140 he nonhydrolysable cAMP analog 8-bromo-cAMP, thyrotropin releasing hormone, or cholecystokinin reveal

141 ysis showed that proteolytic cleavage of pro-thyrotropin-releasing hormone (proTRH) at known PC cleav

142 of 5-hydroxytryptamine (serotonin, 5-HT) and thyrotropin-releasing hormone (TRH) act synergistically

143 n-Leu-Pro-Gly, a progenitor sequence for the thyrotropin-releasing hormone (TRH) analogue [Leu(2)]TRH

144 Metabolically stable and centrally acting thyrotropin-releasing hormone (TRH) analogues were desig

145 has an important action on hypophysiotropic thyrotropin-releasing hormone (TRH) and corticotropin-re

146 roximately 55%, 35% and 63% of somatostatin, thyrotropin-releasing hormone (TRH) and corticotropin-re

147 cifically from subsets of neurons expressing thyrotropin-releasing hormone (TRH) and pituitary adenyl

148 nism of trans-repression of the hypothalamic thyrotropin-releasing hormone (TRH) and pituitary thyroi

149 y and pontine raphe and receives inputs from thyrotropin-releasing hormone (TRH) and substance P-expr

150 pituitary-thyroid (HPT) axis hormones, i.e., thyrotropin-releasing hormone (TRH) and thyrotropin (TSH

151 We show that several analogs of thyrotropin-releasing hormone (TRH) are more efficacious

152 To test whether pro-thyrotropin-releasing hormone (TRH) conversion to TRH in

153 Hypothalamic T3 content is decreased while thyrotropin-releasing hormone (TRH) expression is elevat

154 daptive response is caused by a reduction in thyrotropin-releasing hormone (TRH) expression that can

155 y marginally elevated in transgenic mice and thyrotropin-releasing hormone (TRH) gene expression in t

156 Thyrotropin-releasing hormone (TRH) has previously been

157 y predicting the structure of the tripeptide thyrotropin-releasing hormone (TRH) in solution.

158 ve feedback loop that inhibits production of thyrotropin-releasing hormone (TRH) in the mediobasal hy

159 Thyrotropin-releasing hormone (TRH) increases activity a

160 nin) enhanced GIRK channel currents, whereas thyrotropin-releasing hormone (TRH) inhibited both basal

161 The hypothalamic neuropeptide, thyrotropin-releasing hormone (TRH) inhibits ERG channel

162 In vertebrates thyrotropin-releasing hormone (TRH) is a highly conserve

163 Thyrotropin-releasing hormone (TRH) is a tripeptide that

164 The neuropeptide thyrotropin-releasing hormone (TRH) is recognized to pla

165 Thyrotropin-releasing hormone (TRH) is reported to have

166 in the DMH and in the posterior Pe coexpress thyrotropin-releasing hormone (TRH) mRNA.

167 ed in fibers that innervate hypophysiotropic thyrotropin-releasing hormone (TRH) neurons and modulate

168 LepR are expressed mainly in thyrotropin-releasing hormone (TRH) neurons, some of whi

169 nal and cellular effects of the neuropeptide thyrotropin-releasing hormone (TRH) on the spontaneously

170 Basal [Ca(2+)](cyt) was about 50 nm; thyrotropin-releasing hormone (TRH) or other agonists in

171 jection of peptide YY (PYY) and low doses of thyrotropin-releasing hormone (TRH) or TRH analog, RX 77

172 Raphe-derived serotonin (5-HT) and thyrotropin-releasing hormone (TRH) play important roles

173 ly that left ventricular gene expression for thyrotropin-releasing hormone (TRH) precursor was increa

174 The G protein-coupled thyrotropin-releasing hormone (TRH) receptor is phosphor

175 smembrane helices 5 and 6 (TMH5 and TMH6) of thyrotropin-releasing hormone (TRH) receptor type I (TRH

176 The thyrotropin-releasing hormone (TRH) receptor undergoes r

177 The thyrotropin-releasing hormone (TRH) receptor was express

178 HEK293 cells expressing the thyrotropin-releasing hormone (TRH) receptor were transf

179 We tested whether thyrotropin-releasing hormone (TRH) receptors lacking ph

180 Dimerization and phosphorylation of thyrotropin-releasing hormone (TRH) receptors was charac

181 Here we show that mouse thyrotropin-releasing hormone (TRH) receptors, subtypes

182 Thyrotropin-releasing hormone (TRH) regulates the hypoth

183 Hypothalamic thyrotropin-releasing hormone (TRH) stimulates thyroid-s

184 feedback inhibition of thyrotropin (TSH) and thyrotropin-releasing hormone (TRH) synthesis in the pit

185 Thyrotropin-releasing hormone (TRH) synthesized in medul

186 Galanin, gamma-aminobutyric acid (GABA), and thyrotropin-releasing hormone (TRH) were colocalized wit

187 A binding pocket for thyrotropin-releasing hormone (TRH) within the transmemb

188 the activity of orexin cells is modulated by thyrotropin-releasing hormone (TRH), an endogenous stimu

189 cretin, melanin-concentrating hormone (MCH), thyrotropin-releasing hormone (TRH), gonadotropin-releas

190 ear ER-alpha ir was found in a population of thyrotropin-releasing hormone (TRH)-expressing neurons i

191 beta-Arrestin 2 reduced thyrotropin-releasing hormone (TRH)-stimulated inositol

192 center for the central actions of leptin on thyrotropin-releasing hormone (TRH)-synthesizing neurons

193 lved in the control of thermogenesis such as thyrotropin-releasing hormone (TRH).

194 gulation of several neuropeptides, including thyrotropin-releasing hormone (TRH).

195 ta subunit (TSH-beta) genes is stimulated by thyrotropin-releasing hormone (TRH).

196 and inhibitory modulation of K+ channels by thyrotropin-releasing hormone (TRH).

197 urrent was not sensitive to glibenclamide or thyrotropin-releasing hormone (TRH).

198 dose: 100 nM), compared to that observed for thyrotropin-releasing hormone (TRH, minimum effective do

199 We and others have previously reported that thyrotropin-releasing hormone (TRH, pGlu-His-Pro-NH(2))

200 Thyrotropin-releasing hormone (TRH; protirelin), a brain

201 y cooperative interaction between leptin and thyrotropin-releasing hormone [TRH] to activate hindbrai

202 y cooperative interaction between leptin and thyrotropin-releasing hormone [TRH] to activate hindbrai

203 hormone, corticotropin-releasing factor, and thyrotropin-releasing hormone also stimulated calcium si

204 omatostatin, corticotropin-releasing factor, thyrotropin-releasing hormone and calcitonin gene-relate

205 express corticotrophin-releasing hormone or thyrotropin-releasing hormone and do not express arginin

206 expression was found in PVH cells producing thyrotropin-releasing hormone and in cholinergic DMV cel

207 that CG5911 is evolutionarily related to the thyrotropin-releasing hormone and neuromedin U receptors

208 Some thyrotropin-releasing hormone and neurotensin neurons we

209 ng juvenile chum salmon (Oncorhynchus keta), thyrotropin-releasing hormone gene expression increased

210 ytocin, corticotropin-releasing hormone, and thyrotropin-releasing hormone in an appropriate spatial

211 pattern was clarified including the role of thyrotropin-releasing hormone in synthesis of thyrotropi

212 le metabolism, regulation of food intake, or thyrotropin-releasing hormone levels in the hypothalamus

213 hysiotropic PVH cells coexpress Y1-R and pro-thyrotropin-releasing hormone mRNAs in the rat.

214 The latter is also influenced by thyrotropin-releasing hormone neurons that act centrally

215 ral preoptic nucleus, and a mainly glutamate-thyrotropin-releasing hormone projection to the wake-pro

216 rmore, IGSF1 stimulates transcription of the thyrotropin-releasing hormone receptor (TRHR) by negativ

217 DSGCs: dopamine receptor 4 (DRD4)-DSGCs and thyrotropin-releasing hormone receptor (TRHR)-DSGCs.

218 93 cells co-expressing TREK-1 and either the thyrotropin-releasing hormone receptor (TRHR1) or the Or

219 In contrast, the mammalian thyrotropin-releasing hormone receptor and the African c

220 udy phosphorylation of the endogenous type I thyrotropin-releasing hormone receptor in the anterior p

221 the C-terminal tail of either the mammalian thyrotropin-releasing hormone receptor or the catfish Gn

222 Thyrotropin-releasing hormone receptor type 2 (TRH-R2),

223 tion-selective ganglion cells (dsGCs): TRHR (thyrotropin-releasing hormone receptor) and Drd4 (dopami

224 otensin receptor 1, vasopressin V2 receptor, thyrotropin-releasing hormone receptor, and substance P

225 five structurally diverse antagonists of the thyrotropin-releasing hormone receptors (TRH-R1 and TRH-

226 lex and includes suppression of hypothalamic thyrotropin-releasing hormone, accounting for persistent

227 d by serotonin, norepinephrine, substance P, thyrotropin-releasing hormone, and 3,5-dihydroxyphenylgl

228 n-releasing hormone, oxytocin, somatostatin, thyrotropin-releasing hormone, and vasopressin.

229 than another inducer of prolactin secretion, thyrotropin-releasing hormone, both in vitro and in vivo

230 onadotropin-releasing hormone, somatostatin, thyrotropin-releasing hormone, corticotropin-releasing h

231 with chronic ECS such as neuropeptide Y and thyrotropin-releasing hormone, may provide novel ways to

232 modulation of RTN activity by Substance P or thyrotropin-releasing hormone, previously identified neu

233 rvicellular corticotropin-releasing hormone, thyrotropin-releasing hormone, somatostatin, and dopamin

234 In neuroD2-deficient mice, thyrotropin-releasing hormone, thyroid-stimulating hormo

235 f these channels also disrupted transmitter (thyrotropin-releasing hormone, TRH) inhibition and did s

236 including corticotropin-releasing hormone-, thyrotropin-releasing hormone-, vasopressin-, and oxytoc

237 eport of diurnal variations in the levels of thyrotropin-releasing hormone-like peptides (pGlu-X-Pro-

238 in, corticotropin-releasing hormone (CRH) or thyrotropin-releasing hormone.

239 estphal nucleus was identified as containing thyrotropin-releasing hormone.

240 ted responses to leptin and a suppression of thyrotropin-releasing hormone.

241 thyroid-stimulating hormone and hypothalamic thyrotropin-releasing hormone.

242 ated by food availability via leptin-induced thyrotropin-releasing hormone/thyroid-stimulating hormon

243 ep deprivation, thyrotropin bioactivity, the thyrotropin response to protirelin the next afternoon, a

244 reduced by BRAF(V600E) because of decreased thyrotropin responsiveness associated with inhibition of

245 ecretion were evaluated, including pituitary thyrotropin-secreting adenomas.

246 of hyperthyroidism, including struma ovarii, thyrotropin-secreting tumours, choriocarcinoma, and amio

247 The degree of suppression of thyrotropin secretion tended to be greater in patients t

248 Causes of excessive thyrotropin secretion were evaluated, including pituitar

249 inoid X receptor-selective ligand suppresses thyrotropin secretion.

250 own significantly increased isoproterenol or thyrotropin-stimulated cAMP accumulation.

251 ography and measurement of recombinant human thyrotropin-stimulated thyroglobulin.

252 r randomized, phase 3 trial, we compared two thyrotropin-stimulation methods (thyroid hormone withdra

253 ent between the (131)I doses and between the thyrotropin-stimulation methods.

254 concentrations of T3 but not T4 can suppress thyrotropin subunit beta gene expression.

255 on, use of radioactive iodine, and degree of thyrotropin suppression.

256 oU per milliliter in 3 of the 7 women in the thyrotropin-suppression group.

257 ne-replacement therapy and 7 women receiving thyrotropin-suppressive thyroxine therapy.

258 s 2-5 were higher in patients with low serum thyrotropin than in the rest of the cohort (hazard ratio

259 light of the contemporary use of recombinant thyrotropin (thyroid-stimulating hormone) (rTSH) to prep

260 ted thyroid hormone levels and inappropriate thyrotropin (thyroid-stimulating hormone, or TSH) produc

261 The thyrotropin [thyroid-stimulating hormone (TSH)] receptor

262 Evidence was presented that thyrotropin [thyroid-stimulating hormone (TSH)]-stimulat

263 influenced by using either recombinant human thyrotropin (thyrotropin alfa) or thyroid hormone withdr

264 Thyrotropin (TSH) activation of the TSH receptor (TSHR),

265 Here, for the heritable thyroid traits thyrotropin (TSH) and free thyroxine (FT4), we analyse w

266 In this study we report that thyrotropin (TSH) and the pathogenic, GD-specific monocl

267 ction is regulated by feedback inhibition of thyrotropin (TSH) and thyrotropin-releasing hormone (TRH

268 When elevated thyrotropin (TSH) and/or decreased T4 are found in the b

269 provided that the bioactivity and action of thyrotropin (TSH) are not impaired.

270 autoimmune gastritis, who showed high serum thyrotropin (TSH) levels (in the hypothyroid range) whil

271 had a 3.4-fold (p < 0.02) increase in serum thyrotropin (TSH) levels.

272 AMP is a critical mediator of the effects of thyrotropin (TSH) on cell proliferation and differentiat

273 The thyrotropin (TSH) receptor (TSHR) is a member of the het

274 The thyrotropin (TSH) receptor (TSHR) signals via G proteins

275 e caused by pathogenic autoantibodies to the thyrotropin (TSH) receptor (TSHR), can be treated but no

276 To examine thyrotropin (TSH) receptor homophilic interactions we fu

277 COIP), we previously reported that the human thyrotropin (TSH) receptor tagged with green fluorescent

278 antigen [particularly thyroid peroxidase and thyrotropin (TSH) receptor] and of high affinity monoclo

279 Thyrotropin (TSH) regulates thyroid cell proliferation a

280 In rat thyroid cells, thyrotropin (TSH) stimulates proliferation through a cAM

281 ransient accumulation of intracellular cAMP, thyrotropin (TSH) stimulation of the FRTL-5 thyroid cell

282 s triiodothyronine (T3), thyroxine (T4), and thyrotropin (TSH) were measured in plasma for 4 mo befor

283 hysiologically relevant system that requires thyrotropin (TSH), acting via cAMP, for a full mitogenic

284 .e., thyrotropin-releasing hormone (TRH) and thyrotropin (TSH), are expressed in human hair follicles

285 ne that controls thyroid hormone production, thyrotropin (TSH), caught the attention of skin research

286 Human thyrotropin (TSH), luteotropin (LH), follitropin (FSH),

287 rotein hormones chorionic gonadotropin (CG), thyrotropin (TSH), lutropin (LH), and follitropin (FSH)

288 elevation of thyroid-stimulating hormone, or thyrotropin (TSH), that occurs with hypothyroidism stimu

289 ittle is known about the mechanisms by which thyrotropin (TSH), the main hormonal regulator of thyroi

290 Thyrotropin (TSH), the physiologic regulator of thyroid

291 The G protein-coupled thyrotropin (TSH)-releasing hormone (TRH) receptor forms

292 tudies given the predominant role of cAMP in thyrotropin (TSH)-stimulated proliferation and as an onc

293 studies have addressed the potential role of thyrotropin (TSH).

294 7.9), maternal thyroid function tests (serum thyrotropin [TSH], free thyroxine [fT4], and thyroid per

295 combinant human thyroid-stimulating hormone (thyrotropin; TSH) over the past 2 y.

296 the secretion of T4 induced by injection of thyrotropin was reduced in Mct8-KO in which endogenous T

297 DW/J-Pou1f1dw/dw mutant mice lack pituitary thyrotropin, which causes severe thyroid hormone deficie

298 ) of the pituitary, regulating expression of thyrotropin, which then relays messages back to the hypo

299 ivity; nonresponders compensate by secreting thyrotropin with increased bioactivity.

300 tion responders compensate by secreting more thyrotropin with normal bioactivity; nonresponders compe